Victory Capital Management Inc. Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Victory Capital Management Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 153.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,919 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,825 shares during the quarter. Victory Capital Management Inc. owned about 0.06% of ANI Pharmaceuticals worth $771,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth about $65,000. Ridgewood Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $85,000. O Shaughnessy Asset Management LLC purchased a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $218,000. XTX Topco Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth $207,000. Finally, Profund Advisors LLC purchased a new stake in ANI Pharmaceuticals during the second quarter worth $225,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ ANIP opened at $59.39 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The firm has a market cap of $1.25 billion, a P/E ratio of -107.98 and a beta of 0.71. The firm’s 50 day moving average price is $58.28 and its 200 day moving average price is $60.75. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period last year, the company earned $1.05 EPS. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ANIP shares. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Raymond James lifted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 33,981 shares of company stock worth $1,970,066. 12.70% of the stock is owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.